[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 22/29, 2018

Best Evidence Supports Annual Surveillance for Resected Colorectal Cancer

Author Affiliations
  • 1Division of Hematology/Oncology, University of North Carolina at Chapel Hill
JAMA. 2018;319(20):2083-2085. doi:10.1001/jama.2018.5817

Colorectal cancer is unique in solid tumor oncology because surgical resection for patients with solitary or oligometastatic disease can provide long-term disease-free survival, and even cure.1-5 Largely predicated on the notion that earlier recurrence detection will allow a greater chance of surgery with curative intent, specialty guidelines recommend that patients with stage II or III colorectal cancers should be followed up with a 5-year surveillance program of carcinoembryonic antigen (CEA) testing, computed tomography (CT) scans, and endoscopy.6-10 These guidelines are supported by multiple prior studies on the role and schedule of surveillance, which suggest surveillance increases curative intent surgical resections and improves overall survival.11